ID

35866

Descrizione

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01992952

collegamento

https://clinicaltrials.gov/show/NCT01992952

Keywords

  1. 29/03/19 29/03/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

29 marzo 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Estrogen Receptor Positive Breast Cancer NCT01992952

Eligibility Estrogen Receptor Positive Breast Cancer NCT01992952

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
post-menopausal women
Descrizione

Postmenopausal state

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0232970
life expectancy 3 months
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
histological confirmation of er+ breast cancer
Descrizione

Oestrogen receptor positive breast cancer

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2938924
clinical or histological confirmation of metastatic or locally advanced disease not amenable to surgical resection
Descrizione

Neoplasm Metastasis Inappropriate Excision | Advanced disease Locally Inappropriate Excision

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0728940
UMLS CUI [2,1]
C0679246
UMLS CUI [2,2]
C1517927
UMLS CUI [2,3]
C1548788
UMLS CUI [2,4]
C0728940
measurable or non-measurable disease
Descrizione

Measurable Disease | Non-Measurable Lesion

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1334988
adequate bone marrow, renal and hepatic function
Descrizione

Bone Marrow function | Renal function | Liver function

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
eastern cooperative oncology group (ecog) performance status < or equal to 2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
progressive disease whilst receiving an aromatase inhibitor (ai) for metastatic breast cancer (mbc)
Descrizione

Progressive Disease | Aromatase Inhibitor Secondary malignant neoplasm of female breast

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1335499
UMLS CUI [2,1]
C0593802
UMLS CUI [2,2]
C0346993
relapsed with metastatic disease whilst receiving an ai in adjuvant setting
Descrizione

Metastatic/Recurrent Disease | Aromatase Inhibitor Adjuvant therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1334739
UMLS CUI [2,1]
C0593802
UMLS CUI [2,2]
C0677850
up to 3 prior lines endocrine therapy for mbc
Descrizione

Hormone Therapy Quantity Secondary malignant neoplasm of female breast

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346993
up to 1 line of chemotherapy in the metastatic setting
Descrizione

Chemotherapy Quantity Neoplasm Metastasis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0027627
patient willing to donate archival tumour sample
Descrizione

Tumor tissue sample Donation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C0680854
patient willing to donate baseline blood sample
Descrizione

Blood specimen Donation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0178913
UMLS CUI [1,2]
C0680854
adequate bone marrow and organ function
Descrizione

Bone Marrow function | Organ function

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0678852
suitable for further endocrine therapy
Descrizione

Suitable Hormone Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3900053
UMLS CUI [1,2]
C0279025
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with fulvestrant or pi3k/mtor(mammalian target of rapamycin )/akt inhibitor therapy
Descrizione

fulvestrant | Phosphatidylinositide 3-Kinase Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0935916
UMLS CUI [2]
C1519050
UMLS CUI [3]
C2746052
UMLS CUI [4,1]
C0812228
UMLS CUI [4,2]
C1999216
UMLS CUI [5,1]
C0812230
UMLS CUI [5,2]
C1999216
UMLS CUI [6,1]
C1332074
UMLS CUI [6,2]
C1999216
clinically significant abnormalities in glucose metabolism
Descrizione

Glucose metabolism abnormal

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1142273
rapidly progressive visceral disease not suitable for further endocrine therapy
Descrizione

Disease Visceral Rapidly progressive | Hormone Therapy Inappropriate

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0442045
UMLS CUI [1,3]
C1838681
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C1548788
known brain or leptomeningeal metastases
Descrizione

Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C1704231
any co-existing medical condition precluding trial entry including significant cardiac disease (to be defined in the protocol)
Descrizione

Comorbidity Study Subject Participation Status Excluded | Heart Disease Significant

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C0332196
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C0750502
concomitant medication unsuitable for combination with trial medication
Descrizione

Pharmaceutical Preparations Inappropriate Combination Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0205195
UMLS CUI [1,4]
C0013230

Similar models

Eligibility Estrogen Receptor Positive Breast Cancer NCT01992952

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state
Item
post-menopausal women
boolean
C0232970 (UMLS CUI [1])
Life Expectancy
Item
life expectancy 3 months
boolean
C0023671 (UMLS CUI [1])
Oestrogen receptor positive breast cancer
Item
histological confirmation of er+ breast cancer
boolean
C2938924 (UMLS CUI [1])
Neoplasm Metastasis Inappropriate Excision | Advanced disease Locally Inappropriate Excision
Item
clinical or histological confirmation of metastatic or locally advanced disease not amenable to surgical resection
boolean
C0027627 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0728940 (UMLS CUI [1,3])
C0679246 (UMLS CUI [2,1])
C1517927 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
C0728940 (UMLS CUI [2,4])
Measurable Disease | Non-Measurable Lesion
Item
measurable or non-measurable disease
boolean
C1513041 (UMLS CUI [1])
C1334988 (UMLS CUI [2])
Bone Marrow function | Renal function | Liver function
Item
adequate bone marrow, renal and hepatic function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status < or equal to 2
boolean
C1520224 (UMLS CUI [1])
Progressive Disease | Aromatase Inhibitor Secondary malignant neoplasm of female breast
Item
progressive disease whilst receiving an aromatase inhibitor (ai) for metastatic breast cancer (mbc)
boolean
C1335499 (UMLS CUI [1])
C0593802 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
Metastatic/Recurrent Disease | Aromatase Inhibitor Adjuvant therapy
Item
relapsed with metastatic disease whilst receiving an ai in adjuvant setting
boolean
C1334739 (UMLS CUI [1])
C0593802 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
Hormone Therapy Quantity Secondary malignant neoplasm of female breast
Item
up to 3 prior lines endocrine therapy for mbc
boolean
C0279025 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
Chemotherapy Quantity Neoplasm Metastasis
Item
up to 1 line of chemotherapy in the metastatic setting
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Tumor tissue sample Donation
Item
patient willing to donate archival tumour sample
boolean
C0475358 (UMLS CUI [1,1])
C0680854 (UMLS CUI [1,2])
Blood specimen Donation
Item
patient willing to donate baseline blood sample
boolean
C0178913 (UMLS CUI [1,1])
C0680854 (UMLS CUI [1,2])
Bone Marrow function | Organ function
Item
adequate bone marrow and organ function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0678852 (UMLS CUI [2])
Suitable Hormone Therapy
Item
suitable for further endocrine therapy
boolean
C3900053 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
fulvestrant | Phosphatidylinositide 3-Kinase Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor
Item
previous treatment with fulvestrant or pi3k/mtor(mammalian target of rapamycin )/akt inhibitor therapy
boolean
C0935916 (UMLS CUI [1])
C1519050 (UMLS CUI [2])
C2746052 (UMLS CUI [3])
C0812228 (UMLS CUI [4,1])
C1999216 (UMLS CUI [4,2])
C0812230 (UMLS CUI [5,1])
C1999216 (UMLS CUI [5,2])
C1332074 (UMLS CUI [6,1])
C1999216 (UMLS CUI [6,2])
Glucose metabolism abnormal
Item
clinically significant abnormalities in glucose metabolism
boolean
C1142273 (UMLS CUI [1])
Disease Visceral Rapidly progressive | Hormone Therapy Inappropriate
Item
rapidly progressive visceral disease not suitable for further endocrine therapy
boolean
C0012634 (UMLS CUI [1,1])
C0442045 (UMLS CUI [1,2])
C1838681 (UMLS CUI [1,3])
C0279025 (UMLS CUI [2,1])
C1548788 (UMLS CUI [2,2])
Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges
Item
known brain or leptomeningeal metastases
boolean
C0220650 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Comorbidity Study Subject Participation Status Excluded | Heart Disease Significant
Item
any co-existing medical condition precluding trial entry including significant cardiac disease (to be defined in the protocol)
boolean
C0009488 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C0018799 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Pharmaceutical Preparations Inappropriate Combination Investigational New Drugs
Item
concomitant medication unsuitable for combination with trial medication
boolean
C0013227 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0205195 (UMLS CUI [1,3])
C0013230 (UMLS CUI [1,4])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial